List of Excipients in Branded Drug BASIC CARE DUAL ACTION COMPLETE

Generic Drugs Containing BASIC CARE DUAL ACTION COMPLETE

Company	Ingredient	NDC	Excipient
L Perrigo Company	famotidine, calcium carbonate and magnesium hydroxide	0113-7321	ANHYDROUS LACTOSE
L Perrigo Company	famotidine, calcium carbonate and magnesium hydroxide	0113-7321	ASPARTAME
L Perrigo Company	famotidine, calcium carbonate and magnesium hydroxide	0113-7321	CELLULOSE, MICROCRYSTALLINE
L Perrigo Company	famotidine, calcium carbonate and magnesium hydroxide	0113-7321	D&C RED NO. 7

What are the Most Frequently-Used Excipients in BASIC CARE DUAL ACTION COMPLETE?

# Of NDCs	Excipient
2	ANHYDROUS LACTOSE
2	ASPARTAME
2	CELLULOSE, MICROCRYSTALLINE
2	D&C RED NO. 7

Basic Care Dual Action Complete: Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Basic Care Dual Action Complete is an over-the-counter combination analgesic that pairs acetaminophen and ibuprofen. The commercial opportunity is primarily in cost-efficient formulation, tablet performance, retailer differentiation, and line extensions rather than in patent exclusivity. Public product labeling identifies the active-ingredient strength as acetaminophen 250 mg and ibuprofen 125 mg per caplet, matching the dual-action positioning used by comparable products.[1]

What is Basic Care Dual Action Complete?

Basic Care Dual Action Complete is a nonprescription oral analgesic and antipyretic. Each caplet contains:

Component	Strength per caplet	Pharmacological role
Acetaminophen	250 mg	Analgesic and antipyretic
Ibuprofen	125 mg	NSAID analgesic, antipyretic and anti-inflammatory

The labeled adult and pediatric use for individuals 12 years and older is generally two caplets every eight hours, with a maximum of six caplets in 24 hours. At the maximum labeled daily dose, the consumer receives 1,500 mg of acetaminophen and 750 mg of ibuprofen.[1]

The product is positioned for temporary relief of minor aches and pains, including headache, backache, toothache, menstrual cramps, muscular aches and arthritis-related pain. Its commercial proposition is combination efficacy with fewer units per dose than taking separate acetaminophen and ibuprofen products.

How does the product compare with Advil Dual Action?

Basic Care Dual Action Complete appears to compete directly with Advil Dual Action, which uses the same 250 mg acetaminophen and 125 mg ibuprofen strength per caplet. The principal differences are likely to be brand equity, price, package size, retailer placement and manufacturing economics rather than active-ingredient composition.

Attribute	Basic Care Dual Action Complete	Advil Dual Action
Active ingredients	Acetaminophen 250 mg; ibuprofen 125 mg	Acetaminophen 250 mg; ibuprofen 125 mg
Dosage form	Oral caplet	Oral caplet
Regulatory category	OTC analgesic	OTC analgesic
Primary commercial position	Retailer/private-label value	National brand
Orange Book dependence	Low	Low
Main differentiation levers	Price, pack count, tablet quality, availability	Brand recognition and marketing

The private-label product can compete effectively if it maintains equivalent tablet robustness, dissolution, appearance and packaging while reducing brand and promotional costs.

What excipients are likely used in Basic Care Dual Action Complete?

The exact excipient composition should be taken from the current package insert, labeler filing or manufacturing specification. Public consumer-facing labeling often identifies inactive ingredients, but private-label products may change suppliers or manufacturing sites without changing the active-ingredient label.

A caplet containing 375 mg of active pharmaceutical ingredients typically requires excipients in several functional categories:

Excipient function	Common candidate materials	Commercial purpose
Diluent or filler	Microcrystalline cellulose, lactose, dibasic calcium phosphate	Adds tablet mass and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes breakup after ingestion
Lubricant	Magnesium stearate, stearic acid	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Film former	Hypromellose, polyvinyl alcohol	Protects the tablet and improves swallowability
Plasticizer	Polyethylene glycol or triacetin	Improves film flexibility
Opacifier or pigment	Titanium dioxide, iron oxides or other permitted colorants	Controls appearance and light protection
Surface treatment	Talc or polishing agents	Supports coating and tablet finish

Why is excipient selection difficult for this combination?

Acetaminophen and ibuprofen have different physicochemical and processing characteristics. Acetaminophen is present at twice the mass of ibuprofen in the labeled combination, while ibuprofen can create flow, lubrication and content-uniformity challenges. The formulation must also manage:

1. Uniform distribution of both active ingredients.
2. Adequate tablet hardness without delaying dissolution.
3. Low sticking and picking during compression.
4. Acceptable taste and mouthfeel if the coating is damaged.
5. Stability under heat and humidity.
6. Consistent dissolution for both active ingredients.
7. Caplet size that remains acceptable for repeated consumer use.

A robust formulation will usually require more than simply blending the two active ingredients with a conventional direct-compression filler.

What excipient strategy supports commercial-scale manufacturing?

The strongest commercial strategy is a conventional, scalable immediate-release caplet using widely available excipients with established regulatory histories.

Direct compression versus wet granulation

Direct compression offers lower processing cost, fewer manufacturing steps and reduced exposure to water. It is attractive where both active ingredients have suitable flow and compressibility.

Wet granulation can improve content uniformity and tablet strength, particularly when the two active ingredients have different particle-size distributions or poor flow. It increases process complexity, energy consumption and validation requirements.

A manufacturer evaluating a private-label version would likely compare:

Manufacturing route	Advantages	Main risks
Direct compression	Low cost, short process, limited equipment	Segregation, poor flow, weight variation
Dry granulation	Better flow and density without water	Ribbon variability, granule overcompression
Wet granulation	Strong content uniformity and tablet robustness	Moisture exposure, longer cycle, higher cost
Separate granulation of actives	Better control of each ingredient	More steps and higher manufacturing cost

For a high-volume retail product, direct compression or dry granulation may provide the best cost position if dissolution and content-uniformity targets are met.

Disintegrant and dissolution design

The product must release both active ingredients promptly. Excessive compression force, high lubricant levels or an overly dense film coat can slow disintegration and dissolution.

Croscarmellose sodium, crospovidone and sodium starch glycolate are common development choices. Crospovidone may be attractive where rapid wicking is needed. Croscarmellose sodium can provide strong swelling and breakup performance. Sodium starch glycolate is effective at low concentrations but may be sensitive to formulation and compression conditions.

The excipient choice is not independently patentable in most cases. Its value lies in manufacturing reproducibility, quality performance and cost control.

Coating strategy

A thin film coat can improve swallowability, protect the tablet from handling damage and create a distinctive private-label appearance. The coating must not compromise dissolution or create a large caplet that consumers reject.

Potential commercial improvements include:

• Lower-friction coating for easier swallowing.
• Reduced coating weight to lower cost.
• Color coding that differentiates the product from single-ingredient analgesics.
• Printing or embossing that improves identification.
• Moisture-barrier packaging for warehouse and household stability.

What formulation patents protect dual-action analgesics?

The active ingredients acetaminophen and ibuprofen are established small molecules with extensive prior art. A simple combination of the two ingredients has limited exclusivity potential because the combination, dosage strengths and analgesic use are publicly known and marketed by multiple companies.

Potentially protectable subject matter could include:

• A specific immediate-release formulation.
• A multilayer tablet separating the two actives.
• A bilayer or core-shell dosage form.
• Modified-release delivery of one active ingredient.
• Taste-masking or swallowability technology.
• A defined particle-size distribution.
• A manufacturing process that improves uniformity.
• A stability-enhancing packaging and formulation system.
• A fixed-dose combination with a novel dosing schedule.

A formulation patent would need claims that distinguish the product from existing acetaminophen, ibuprofen and combination products. Routine selection of standard binders, lubricants and disintegrants would face substantial obviousness risk under U.S. patent law.

What is the FDA regulatory status of Basic Care Dual Action Complete?

The product is an OTC analgesic combination regulated under the FDA monograph framework for internal analgesic, antipyretic and antirheumatic products. Acetaminophen and ibuprofen are established OTC active ingredients with defined labeling and safety requirements.[2]

The product does not require the same regulatory pathway as a new molecular entity. Commercialization generally depends on compliance with:

• Applicable OTC monograph conditions.
• Drug Facts labeling requirements.
• Current good manufacturing practice requirements.
• Finished-product identity, strength, quality and purity specifications.
• Stability and packaging controls.
• Adverse-event reporting obligations.
• Tamper-evident packaging requirements where applicable.

Is Basic Care Dual Action Complete listed in the Orange Book?

The Orange Book primarily covers approved prescription drugs and certain approved drug products with therapeutic-equivalence determinations. An OTC monograph product is not normally dependent on an Orange Book listing for its market position.

The commercial barrier for Basic Care Dual Action Complete is therefore regulatory compliance and manufacturing qualification, not a listed patent term. The product also has no biosimilar issue because it is a conventional small-molecule drug, not a biologic.

When does Basic Care Dual Action Complete lose exclusivity?

Basic Care Dual Action Complete does not appear to rely on meaningful product-specific exclusivity. Its market protection comes from the Basic Care private-label brand, retailer control and supply arrangements.

Exclusivity category	Relevance
New chemical entity exclusivity	Not applicable
New drug application exclusivity	Generally not central to monograph marketing
Orphan exclusivity	Not applicable
Biologic exclusivity	Not applicable
Orange Book patent exclusivity	Not the primary commercial mechanism
Trademark protection	Relevant to the Basic Care brand
Retailer/private-label access	Major practical barrier
Manufacturing and supply qualification	Major operational barrier

Competitors can market equivalent acetaminophen/ibuprofen products if they comply with FDA requirements and avoid valid formulation or trademark claims. Paragraph IV litigation is unlikely to be the central competitive mechanism because the product is not principally protected by an Orange Book-listed patent estate.

What commercial opportunities exist for excipient innovation?

The best opportunities are incremental and platform-oriented.

Lower-cost private-label equivalents

A manufacturer can offer retailers a lower-cost product by optimizing:

• Active-material sourcing.
• Granulation yield.
• Tablet weight.
• Coating weight.
• Packaging component cost.
• Line speed.
• Reject rate.
• Supply redundancy.

An excipient system that supports direct compression and high-speed coating can produce greater value than a novel but expensive delivery technology.

Premium swallowability

Caplet size is a significant consumer issue for combination analgesics. A smaller, denser tablet, smoother film coat or improved shape could support a premium product tier. The formulation must preserve dissolution and avoid excessive compression that causes delayed release.

Fast-onset positioning

A rapid-disintegration formulation could support differentiated marketing if the sponsor generates appropriate performance data and complies with FDA labeling rules. Potential development approaches include optimized disintegrant systems, porous granules and reduced hydrophobic lubricant levels.

The phrase "fast acting" or similar claims requires substantiation and must remain consistent with permitted OTC labeling.

Moisture and stability improvements

Acetaminophen and ibuprofen formulations can encounter stability challenges associated with moisture, heat, coating defects and packaging permeability. Commercial improvements may include:

• High-barrier blister packaging.
• Desiccant-containing bottles.
• Moisture-resistant film coats.
• Reduced residual moisture.
• Better control of excipient water activity.
• Improved container-closure systems.

Packaging innovation may offer a more practical protection route than a formulation patent.

Pediatric and geriatric formats

The current caplet format is directed primarily to consumers 12 years and older. Potential extensions include:

• Smaller caplets.
• Easy-swallow tablets.
• Orally disintegrating tablets.
• Liquid suspensions.
• Unit-dose sachets.
• Travel packs.

These formats create technical challenges. Ibuprofen has limited aqueous solubility, and a liquid combination requires suspension stability, taste masking, preservative control and dose uniformity. A liquid product could therefore have higher development and manufacturing costs than a caplet.

What manufacturing and intellectual-property barriers exist?

The main barriers are operational:

1. Reliable sourcing of pharmaceutical-grade acetaminophen and ibuprofen.
2. Control of particle-size distribution and bulk density.
3. Prevention of segregation during blending.
4. Stable dissolution across production lots.
5. High-speed compression without sticking.
6. Consistent coating and appearance.
7. Qualified packaging that controls moisture.
8. Retailer approval and supply-chain performance.

Patent risk is more likely to arise from a third-party formulation, manufacturing or delivery patent than from the active ingredients themselves. A freedom-to-operate review should cover U.S. and foreign patents involving fixed-dose acetaminophen/ibuprofen products, multilayer tablets, rapid-release systems, particle engineering and manufacturing processes.

What is the competitive landscape for dual-action analgesics?

The category includes national brands, store brands and single-ingredient alternatives.

Product class	Competitive advantage	Limitation
Acetaminophen alone	Broad consumer familiarity; no NSAID exposure	Lower anti-inflammatory positioning
Ibuprofen alone	Anti-inflammatory activity	NSAID warnings and gastrointestinal considerations
Fixed-dose combination	Convenience and complementary mechanisms	More complex safety labeling
National-brand combination	Brand trust and advertising	Higher retail price
Store-brand combination	Price and retailer placement	Lower consumer recognition

The main commercial threat to Basic Care is substitution by lower-priced private-label products or separate generic acetaminophen and ibuprofen products. The main opportunity is retailer-exclusive distribution supported by consistent product availability and low unit cost.

Key Takeaways

• Basic Care Dual Action Complete is an OTC fixed-dose combination of acetaminophen 250 mg and ibuprofen 125 mg per caplet.
• Its commercial position is based on private-label pricing and retailer access, not new-molecule exclusivity.
• The most important excipient goals are content uniformity, rapid disintegration, tablet robustness, coating performance and low manufacturing cost.
• Microcrystalline cellulose, povidone, croscarmellose sodium or crospovidone, magnesium stearate, colloidal silicon dioxide and hypromellose are plausible functional excipient classes, but the exact formula must be confirmed from the current product record.
• Direct compression or dry granulation is likely to offer the strongest cost profile if powder flow and uniformity can be controlled.
• Formulation patents covering routine excipient combinations face meaningful prior-art and obviousness risks.
• Fast-disintegrating, smaller, easier-to-swallow and moisture-stable formats offer the clearest product-development opportunities.
• Orange Book, Paragraph IV and biosimilar issues are secondary because this is an OTC small-molecule combination product.
• Manufacturing qualification, supply reliability, packaging and retailer relationships are the primary market barriers.

FAQs About Basic Care Dual Action Complete

Can a company launch a generic equivalent to Basic Care Dual Action Complete?

Yes, subject to compliance with the applicable OTC monograph, labeling, quality and manufacturing requirements. The sponsor must also avoid infringement of any valid third-party formulation, process or trademark rights.

Is Basic Care Dual Action Complete a patented drug?

The active ingredients are established and widely used. The product does not appear to depend on new-chemical-entity protection. Any relevant protection would more likely concern a specific formulation, process, package or brand.

Can the product be reformulated with different excipients?

Yes. A manufacturer can generally change inactive ingredients if the finished product remains compliant with applicable quality, safety, stability, dissolution and labeling requirements.

Is a liquid version commercially attractive?

A liquid version could expand use among consumers who cannot swallow caplets, but ibuprofen solubility, taste masking, suspension stability and dose uniformity create higher technical and cost requirements.

What is the strongest opportunity for an excipient supplier?

The strongest opportunity is a validated immediate-release excipient platform that improves powder flow, content uniformity, compression speed and dissolution while reducing granulation or coating costs.

References

1. DailyMed. (n.d.). Basic Care Dual Action Complete acetaminophen and ibuprofen tablet, film coated: Drug facts label. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). OTC monograph M013: Internal analgesic, antipyretic, and antirheumatic drug products. FDA.
3. U.S. Food and Drug Administration. (2023). DrugFacts label requirements for over-the-counter human drug products. FDA.
4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice requirements for finished pharmaceuticals, 21 C.F.R. Parts 210 and 211. FDA.
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.